FDA approves Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Study: Children with vision impairment have reduced quality of life
Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.
Iveric Bio releases 24-month topline results from Phase 3 study of avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy
According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.
FDA approves avacincaptad pegol intravitreal solution for treatment of geographic atrophy
The complement C5 inhibitor significantly reduced GA progression.
Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US
According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.
FDA issues CRL for Outlook Therapeutics’ ONS-5010
The FDA determined it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
Regeneron receives FDA approval for aflibercept injection 8mg for treatment of wet AMD, DME, DR
According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
Data for aflibercept 8 mg shows durable vision gains at extended dosing intervals for wet AMD
According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.
First investigational eye drop for front and back of the eye met both primary endpoints in Phase 3 OPTIMIZE Trial
Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
Euclid founder George Glady passes away at 73
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
Paul Hahn, MD, PhD, shares insights on pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy
Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.
Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
Visgenx announces positive results from key translational study for its gene therapy candidate for dry AMD
A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.
Prevent Blindness declares June 28 to July 4 Fireworks Safety Awareness Week
Sparklers and firecrackers are at the top of the list for fireworks-related injuries. The organization is advising the public to leave fireworks to licensed operators.
AI used to advance drug delivery system for glaucoma and other chronic diseases
The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
New FDA blood donor recommendations could ease restrictions on cornea donations from queer men
The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.
New lens analysis approach could improve treatments for myopia
Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.
Alimera completes recruitment for its NEW DAY study
According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.
ASCRS 2023: Protecting against eye injuries in sports
Lori Pacheco, RN, CRNO, discussed sports-related eye injuries and how to prevent them at the 2023 ASCRS annual meeting in San Diego.
BREAKING NEWS: Eyenovia Announces FDA approval of Mydcombi, first ophthalmic spray for mydriasis
Mydcombi is the first FDA-approved, fixed-combination of tropicamide and phenylephrine for the reversal of mydriasis.
Glaukos announces FDA acceptance of NDA submission for iDose TR
The iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has a PDUFA date of December 22, 2023.
ASCRS 2023: Harrow to launch FDA-approved chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia
According to the company, clinical trials of the ophthalmic gel showed that patients treated with IHEEZO did not require any supplemental treatment to complete the intended surgical procedure. Harrow will host several launch events at the 2023 American Society of Cataract and Refractive Surgery annual meeting being held May 5-8, 2023, in San Diego, California.
ASCRS 2023: Companies presenting clinical data and technology at annual meeting
Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.
ASCRS to shine in San Diego
New and returning special events and features on tap at annual meeting
Apellis partnering with actor Henry Winkler to bring happy days to fight against geographic atrophy
The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.
ARVO 2023: Human donor tissue to identify mechanism of retinal pigment epithelium death
Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.
ARVO 2023: Lexitas presents its modified NEI scale
Andrew Pucker, OD, MS, PhD, FAAO, and George Magrath, MD, discuss Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.
ARVO 2023: Managing myopia progression with low concentration atropine
Mark Bullimore, PhD, MCOptom, shares a brief overview of her presentation on myopia management by slowing progression with low concentration atropine.
Kala Pharmaceuticals receives FDA Fast Track Designation for KPI-012 for treatment of PCED
According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.
2 Clarke Drive Cranbury, NJ 08512